Capital at the Crossroads: Navigating Today’s Life Sciences Market Realities with ThinkEquity and Nasdaq

Dentons is launching a new roundtable series for biotech, pharma and med device leaders—bringing market experts and investors together to share clear perspectives on today’s capital markets, from current challenges to emerging opportunities.

Episode 1: State of the Markets

Our first session will spotlight the realities of today’s financing and deal-making climate. Hear directly from Tara Sharif, PhD, MBA, Managing Director at ThinkEquity and Andy Hall, Senior Managing Director at Nasdaq as they share perspectives on where the markets stand, what’s moving the needle and what companies should be preparing for in the year ahead.

Guiding the conversation will be Dentons’ own Ira Kotel and Rob Condon, who bring decades of experience at the intersection of life sciences and capital markets. Together, they’ll frame the discussion around practical insights for companies considering fundraising, public listings or strategic transactions.

Key topics include:

• Current fundraising conditions and how they are reshaping biotech, pharma and med device strategies.
• IPO and follow-on market activity—what it takes to go public in today’s climate.
• M&A and partnership trends, including what acquirers and investors are looking for.